Elicio Therapeutics, Inc.
NASDAQ:ELTX · NASDAQ Global Market
+$0.91 today
Vol 4.82M · Avg 0.13M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ELTX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$40.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.36, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 -100.0% | $28.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.1M -4.2% | $1.2M +0.7% | $1.2M +10.7% | $1.1M -14.3% | $1.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.1M +4.2% | -$1.2M -0.7% | -$1.2M -10.7% | -$1.1M -103.9% | $27.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | 95.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $24.9M -26.0% | $33.7M +48.4% | $22.7M +33.0% | $17.0M -64.9% | $48.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $12.8M +13.1% | $11.3M -4.8% | $11.9M +111.3% | $5.6M -68.3% | $17.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $36.6M -16.5% | $43.8M +26.7% | $34.6M +52.5% | $22.7M -65.8% | $66.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.1M -4.2% | $1.2M +0.7% | $1.2M +10.7% | $1.1M +32.0% | $801.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$37.3M +25.8% | -$50.3M -52.5% | -$33.0M -40.0% | -$23.6M +54.6% | -$51.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | -183.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$37.7M +16.2% | -$45.0M -25.9% | -$35.7M -50.6% | -$23.7M +39.6% | -$39.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | -138.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $776.0K -0.1% | $777.0K +108.3% | $373.0K +475.4% | $64.8K +1811.2% | $3.4K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.1M +149.0% | $455.0K -57.0% | $1.1M -70.5% | $3.6M +310.3% | $876.4K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.9M +73.1% | -$6.9M -1356.7% | $550.0K +112.3% | -$4.5M +70.7% | -$15.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$39.6M +23.8% | -$51.9M -47.5% | -$35.2M -24.8% | -$28.2M +48.3% | -$54.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | -192.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$39.6M +23.8% | -$51.9M -47.5% | -$35.2M -24.8% | -$28.2M -6.8% | -$26.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | -93.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 +39.3% | -$4 +38.9% | -$7 +23.5% | -$9 +52.9% | -$19 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 +39.3% | -$4 +38.9% | -$7 +23.5% | -$9 +52.9% | -$19 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $15.3M +25.5% | $12.2M +141.3% | $5.1M +63.1% | $3.1M -3.1% | $3.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $15.3M +25.5% | $12.2M +141.3% | $5.1M +63.1% | $3.1M -3.1% | $3.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Actuate Therapeutics Inc
ACTU
$48.33M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ELTX generate?
Elicio Therapeutics, Inc. (ELTX) reported $0.00 of revenue in fiscal 2025.
Is ELTX profitable?
Elicio Therapeutics, Inc. (ELTX) reported -$39,571,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.